# CJC-1295 References: The Cited Studies and Source Documents

> CJC-1295 references: the full citation list behind this site's figures, with PMIDs and DOIs — Teichman 2006, Ionescu 2006, Jette 2005, Alba 2006, and the GHRH-analog reviews.

Every figure on this site resolves to one of the studies below. Each carries its PMID or DOI so the original record can be checked directly.

## How to read this list

These CJC-1295 references are the source record behind every quantitative claim on the site. The core human pharmacokinetic findings come from Teichman 2006 [1] and Ionescu/Frohman 2006 [3]; the foundational albumin-bioconjugate identification is Jette 2005 [2]; the once-daily growth-normalization result is Alba 2006 [7]. The remaining entries cover the proteomic fingerprint, the GHRH/sleep link, supporting ipamorelin and tesamorelin pharmacology, the IGF-1/cancer epidemiology, and recent reviews of the GHRH-analog class. PMIDs link to PubMed; DOIs resolve to the publisher of record. Where the published record disagrees on a detail — for example the exact molecular formula across chemical registries — that is a property of the sources, not an omission here.

## The human CJC-1295 record

The direct human evidence for CJC-1295 is small and worth naming individually. Teichman 2006 established the dose-dependent multi-day GH/IGF-1 kinetics and the 5.8-8.1 day half-life in healthy adults [1]. Ionescu and Frohman 2006 showed that pulsatile GH secretion persists under continuous stimulation — the preserved-rhythm finding [3]. Sackmann-Sala 2009 added a serum-proteome fingerprint that tracked with IGF-1 [5]. These early-phase studies are the entirety of the controlled human pharmacokinetic record; there are no large efficacy or long-term safety trials in healthy adults, and a Phase 2 program in HIV-associated visceral obesity (NCT00267527) was discontinued.

## Preclinical, class, and context studies

The animal and mechanistic backbone comes from Jette 2005, which identified CJC-1295 as the long-lasting albumin-bioconjugate GRF analog and reported the 4-fold GH AUC in rats [2], and Alba 2006, which normalized growth in the GHRH-knockout mouse on a once-daily schedule [7]. Class context comes from the GHRH/sleep work of Steiger 1992 [6], the ipamorelin pharmacology of Raun 1998 [4] and supporting PK-PD and bone studies [8][9], the tesamorelin trial record [12][13], the IGF-1/cancer epidemiology of Renehan 2004 [14], and recent reviews and methods spanning the GHRH-analog class and its anti-doping detection [10][11].

## References

[1] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[2] Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. https://pubmed.ncbi.nlm.nih.gov/15817669/
[3] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/
[4] Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. https://pubmed.ncbi.nlm.nih.gov/9849822/
[5] Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. https://pubmed.ncbi.nlm.nih.gov/19386527/
[6] Steiger A, Guldner J, Hemmeter U, et al. Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in normal men. Neuroendocrinology. 1992;56(4):566-573. https://pubmed.ncbi.nlm.nih.gov/1361964/
[7] Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. https://pubmed.ncbi.nlm.nih.gov/16822960/
[8] Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. https://pubmed.ncbi.nlm.nih.gov/10496658/
[9] Svensson J, Lall S, Dickson SL, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation. Growth Horm IGF Res. 2001;11(Suppl A):S64-S65 (and related work, Bone 2000). https://pubmed.ncbi.nlm.nih.gov/11735244/
[10] Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. https://pubmed.ncbi.nlm.nih.gov/39537825/
[11] Neuroendocrine circuit for sleep-dependent growth hormone release. Cell. 2025. https://pubmed.ncbi.nlm.nih.gov/40562026/
[12] Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor analog (tesamorelin, TH9507) in HIV-infected patients with excess abdominal fat. J Clin Endocrinol Metab. 2010 (and related Phase 3 reports). https://pubmed.ncbi.nlm.nih.gov/20554713/
[13] Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin. Obes Res Clin Pract. 2026. https://pubmed.ncbi.nlm.nih.gov/41545261/
[14] Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. https://pubmed.ncbi.nlm.nih.gov/15110491/

---

A night-tracker readout of the CJC-1295 record — every GH and IGF-1 figure logged to its study like a recovery stat, the DAC-versus-no-DAC half-life kept on separate rings, and the missing human-safety data left openly blank; no clinic behind the tracker and nothing here dispensed or sold.